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Purpose:
To examine whether cardiac chemical exchange saturation transfer (CEST) imaging can be serially and noninvasively used to probe cell survival or rejection after intramyocardial implantation in mice.
Materials and Methods:
Experiments were compliant with the National Institutes of Health Guidelines on the Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee. One million C2C12 cells labeled with either europium (Eu) 10-(2-hydroxypropyl)-1,4,7-tetraazacyclododecane-1,4,7-triacetic acid (HP-DO3A) or saline via the hypotonic swelling technique were implanted into the anterior-lateral left ventricular wall in C57BL/6J (allogeneic model, n = 17) and C3H (syngeneic model, n = 13) mice. Imaging (frequency offsets of 615 parts per million) was performed 1, 10, and 20 days after implantation, with the asymmetrical magnetization transfer ratio (MTR asym ) calculated from image pairs. Histologic examination was performed at the conclusion of imaging. Changes in MTR asym over time and between mice were assessed by using twoway repeated-measures analysis of variance.
Results:
MTR asym was significantly higher in C3H and C57BL/6J mice in grafts of Eu-HP-DO3A-labeled cells (40.2% 6 5.0 vs 37.8% 6 7.0, respectively) compared with surrounding tissue (20.67% 6 1.7 vs 21.8% 6 5.3, respectively; P , .001) and saline-labeled grafts (20.4% 6 6.0 vs 21.2% 6 3.6, respectively; P , .001) at day 1. In C3H mice, MTR asym remained increased (31.3% 6 9.2 on day 10, 28.7% 6 5.2 on day 20; P , .001 vs septum) in areas of in Eu-HP-DO3A-labeled cell grafts. In C57BL/6J mice, corresponding MTR asym values (11.3% 6 8.1 on day 10, 5.1% 6 9.4 on day 20; P , .001 vs day 1) were similar to surrounding myocardium by day 20 (P = .409). Histologic findings confirmed cell rejection in C57BL/6J mice. Estimation of graft area was similar with cardiac CEST imaging and histologic examination (R 2 = 0.89).
Conclusion:
Cardiac CEST imaging can be used to image cell survival and rejection in preclinical models of cell therapy.
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demonstrate cell survival or rejection after intramyocardial implantation in mice.
Materials and Methods

Cell Culture and Labeling
Immortalized mouse skeletal myoblasts (C2C12) were labeled with either europium (Eu) 10-(2-hydroxypropyl)-1,4,7-tetraazacyclododecane-1,4,7-triacetic acid (HP-DO3A, provided by Dr Silvio Aime at the University of Turin, Turin, Italy) or saline by using a hypotonic swelling technique (23) . For control experiments, cells were exposed to hypotonic solution with saline substituted for Eu-HP-DO3A solution. Full details of cell culture and labeling can be found in Appendix E1 (online).
Cell Transplantation
Experiments were performed according to the National Institutes of Health Guidelines on the Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee. Cardiac implantation of cells involved the use of the "pop-out" technique (24) . Mice were anesthetized and maintained with 2% isoflurane in oxygen, the pectoral muscles were dissected at the fourth intercostal space, mosquito oxide nanoparticle-labeled cells (4-7) has raised concerns of altered gene expression, tissue retention of particles after cell death, and difficulty in differentiating between labeled cells and tissue necrosis (2, (8) (9) (10) (11) (12) (13) . Chemical exchange saturation transfer (CEST) MR imaging is an emerging molecular imaging technique wherein the contrast (change in signal intensity) of either paramagnetic CEST agents (14, 15) or CEST-active reporter genes (16) (17) (18) is selectively activated by using radiofrequency irradiation at target specific offset frequencies (19) . Subsequently, paramagnetic CEST-labeled cells or CEST MR imaging reporter gene-expressing cells can be visualized without disruption of underlying MR image integrity. Prior CEST MR imaging studies have been conducted to track paramagnetic CEST-labeled cells in subcutaneous tumor models in mice (14, 15) and image CEST reporter gene-expressing cells implanted in the rodent brain (16) (17) (18) . While CEST MR imaging is suited for cell tracking in cardiac cell therapy, conventional CEST approaches are unsuitable for preclinical cardiac imaging and have been limited to stationary organs and the lungs (20) . Recently, we designed a CEST MR imaging method specifically for preclinical cardiac imaging, termed cardiac CEST imaging (21, 22) and demonstrated the ability to visualize paramagnetic CEST-labeled cells 24 hours after intramyocardial implantation (22) .
In this study, we used two mouse models of cardiac cell therapy: one syngeneic model in which implanted cells derived from the same genetic strain of mice survive and proliferate over time (C3H genetic background) and one allogeneic model in which identical cells implanted into mice on a different genetic background (C57BL/6J) undergo complete rejection after implantation. We hypothesized that CEST contrast generated by paramagnetic CEST-labeled cells is preserved in surviving cell grafts and eliminated in instances of cell rejection. The purpose of this study was to examine whether cardiac CEST can serially and noninvasively be used to n CEST contrast is eliminated in rejected paramagnetic CESTlabeled cells within 20 days after implantation in C57BL/6J mice (5.1% 6 9.4 for cell graft vs 1.1% 6 4.5 for septum, P = .41). On the basis of our previous findings, regions of interest that encompassed the cell graft were defined on day 1 by using a threshold MTR asym value of up to 15% for mice that received Eu-HP-DO3A-labeled cells (22) . At subsequent time points, the same regions of interest were applied by using anatomic details, such as papillary muscles and polar distance from right ventricular insertion points, to guide placement. For mice that received saline-labeled cells, a region of interest was defined retrospectively on the appropriate section on the basis of histologic identification of the cell graft for C3H mice and the identification of the injection site for C57BL/6J mice. Finally, in all mice, an internal control measurement was obtained in the interventricular septum on the section that contained injected cells.
Advances in Knowledge
Estimation of Graft Size
Cardiac CEST measurement of graft size was performed on data acquired 20 days after implantation of Eu-HP-DO3A-labeled cells. On the basis of our prior findings of appropriate threshold values for identifying cell grafts, an MTR asym threshold of up to 15% was used to calculate graft size as a percentage of total myocardial area (22) . Corresponding measures from hematoxylin-eosin-stained tissue sections were calculated by manually contouring blue-stained graft tissue and were expressed as a percentage of total myocardial area.
Biospin MR Imaging, Ettlingen, Germany) by using a cylindrical volume coil for excitation (outer diameter, 11.2 cm; inner diameter, 8.6 cm) and a four-channel phased-array surface coil for detection. Anesthesia involved the use of 1.5% isoflurane in oxygen, and body temperature was maintained (at 37°C) by using circulating water. Electrocardiographic and respiratory gating was performed with a Small Animal Instruments system (SAI, Stonybrook, NY). The site of cell injection was identified 1 day after implantation as areas of disrupted pericardium on long-axis images. For subsequent imaging, the same section location was identified by using the distance from the left ventricular apex and anatomic features, including papillary muscles. To further ensure that data were repeatedly acquired in the same section location, pairs of cardiac CEST images were acquired in two to three sections around the initial site. Briefly, the cardiac CEST pulse sequence uses a constant repetition time gradient-echo readout to drive initial CEST weighting into the steady-state longitudinal magnetization of the myocardium (22) . The acquisition of cine images is electrocardiographically and respiratory gated, with dummy excitation pulses maintaining steady-state conditions. This strategy enables reliable CEST imaging of the rapidly beating mouse heart in the presence of free breathing. 
Data Analysis
Data analysis was performed in Matlab version R2012b (The MathWorks, clamps were used to open the pleural membrane, and the heart was pressed toward the surface while maintaining pressure on the thorax. Approximately 10 6 cells in 10 mL were injected into the anterior-lateral left ventricular midwall by using a 27-gauge needle. Afterward, the heart was returned to the intrathoracic space, followed by evacuation of air and incision closure to prevent pneumothorax. The mice were removed from anesthesia and allowed to recover in room air.
Mouse Models
A total of 17 male C57BL/6J mice and 13 C3H mice (The Jackson Laboratory, Bar Harbor, Maine) were used. Mice from both genetic strains underwent transplantation of either cells labeled with Eu-HP-DO3A or saline-labeled control cells (Table) . Imaging was performed 1 week before cell transplantation and 1, 10, and 20 days after cell transplantation, after which hearts were excised, sectioned, and stained by using hematoxylin-eosin. Separately, the cellular fraction of murine macrophages was quantified from tissue sections from C3H (n = 2) and C57BL/6J (n = 2) mice that received Eu-HP-DO3A-labeled cells via immunostaining (Appendix E1 [online]) with a rat antimouse F4/80 antibody (clone BM8, catalog no. 14-4801-85; eBioscience, San Diego, Calif). C2C12 cells are derived from C3H mice (syngeneic model) and will survive and proliferate after implantation in C3H mice but undergo rejection (allogeneic model) in C57BL/6J mice.
Imaging
Imaging was performed with a 7-T horizontal imaging unit (ClinScan;
of Eu-HP-DO3A eliminated the previously observed CEST contrast in areas of implanted cells within 20 days and was confirmed at histologic examination ( Fig E2 [online] ). In both C3H and C57BL/6J mice, the implantation of saline-labeled (control) C2C12 cells did not result in any change in CEST contrast in areas of either surviving cells or rejected cells (Fig E3 [online] ). Repeated measurement of MTR asym in areas of implanted cells and internal septal control regions demonstrated Representative MTR asym maps acquired 1 and 20 days after implantation and corresponding histologic images (Fig 1) demonstrate the capacity to identify surviving Eu-HP-DO3A-labeled cells on the basis of increased CEST contrast at 15 ppm. Identical imaging of C57BL/6J mice, in which implanted cells underwent rejection, demonstrated increased MTR asym values in the area of implanted Eu-HP-DO3A-labeled cells 24 hours after implantation (Fig 2) . However, rejection of labeled cells and clearance
Statistics
Statistical analysis was performed with SigmaPlot version 13 software (Systat Software, San Jose, Calif). Comparison of MTR asym values between Eu-HP-DO3A-labeled cell grafts, septal regions, and saline-labeled cell grafts and values over time was performed by using two-way repeatedmeasures analysis of variance, with pairwise comparisons made by using the Holm-Sidak method, which was also used for comparison of MTR asym values over time in Eu-HP-DO3A-labeled cell grafts between C3H and C57BL/6J mice. The Student t test was used to compare MTR asym measurements prior to cell implantation and to compare quantification of graft size according to histologic findings. The association of graft size between MR imaging and histologic findings was examined by using Bland-Altman analysis. A Shapiro-Wilk test was used to confirm the normal distribution of all data. A P value of less than .05 was used to indicate a significant difference.
Results
CEST imaging of the heart with the parameters selected for this study yielded a mean signal-to-noise ratio 6 standard deviation of 19.8 arbitrary units (a.u.) 6 4.1 and contrast-to-noise ratios of 7.3 a.u. 6 2.9 and 7.3 a.u. 6 5.6 between myocardium and blood or lung, respectively. The mean MTR asym values measured in the anterior-lateral wall (20.3% 6 1.9 for C3H vs 21.5% 6 1.1 for C57BL/6J, P = .608) and in the septum (1.8% 6 2.2 for C3H vs 0.6% 6 1.1 for C57BL/6J, P = .595) prior to cell transplantation were similar in C3H (n = 7) and C57BL/6J (n = 5) mice (representative images are shown in Fig E1  [online] ). The mean heart rates during the study time course were 499 beats per minute 6 76 and 513 beats per minute 6 63 for C3H and C57BL/6J mice, respectively. Repeated imaging of C3H mice in which implanted C2C12 cells survived demonstrated significantly increased MTR asym values in grafts of Eu-HP-DO3A-labeled cells compared with surrounding myocardium. 
EXPERIMENTAL STUDIES: Tracking of Cell Survival or Rejection in Mouse Models of Cell Therapy
Pumphrey et al declined gradually after implantation and were significantly reduced by 20 days after implantation compared with initial measurements (Fig 3) . In C57BL/6J mice, CEST contrast was significantly increased within grafts of Eu-HP-DO3A-labeled cells 1 day after implantation when compared with septal regions of interest and saline-labeled cell grafts (Fig 3) . However, MTR asym values within regions of labeled cell grafts decreased significantly within 10 days of implantation. By 20 days after implantation, MTR asym values were indistinguishable from either surrounding myocardium (P = .409) or saline-labeled control animals (P = .254). MTR asym values within Eu-HP-DO3A-labeled cell grafts were statistically similar (P = .564) in C3H and C57BL/6J mice 1 day after implantation but were significantly (P , .001) lower in C57BL/6J mice 10 and 20 days after implantation (Fig 3) .
The survival or rejection of C2C12 cell grafts was confirmed by hematoxylineosin staining and assessed as the percentage of total left ventricular myocardial area. In C3H mice, surviving C2C12 cells resulted in similar graft sizes in Eu-HP-DO3A and saline-labeled cell grafts (12.0% 6 3.3 for Eu-HP-DO3A vs 12.9% 6 9.3 for saline, P = .825). The rejection of C2C12 cell grafts in C57BL/6J mice was similar for both Eu-HP-DO3A and saline-labeled cells (1.0% 6 1.0 for Eu-HP-DO3A vs 0.7% 6 0.5 for unlabeled cells, P = .409). Assessment of Eu-HP-DO3A-labeled graft size was similar between cardiac CEST imaging and histologic examination for most grafts but was underestimated by using MR imaging for grafts larger than 12% of ventricular mass (Fig 4) . The coefficient of variation in calculation of graft size was 17%. Staining of isolated tissue sections for murine macrophages (Fig 5) demonstrated that F4/80-positive macrophages accounted for 1.2% 6 0.3 and 0.9% 6 0.1 of the cells in the graft regions for C3H and C57BL/6J mice, respectively.
Discussion
The results of this study demonstrate the application of cardiac CEST MR comparison to internal control regions of interest in the septum and in comparison to regions of interest that contained implanted salinelabeled cells in genetically identical mice (Fig 3) . Within regions of Eu-HP-DO3A-labeled cells, MTR asym values different patterns for surviving cells when compared with cells undergoing rejection (Fig 3) . In C3H mice, the CEST contrast in tissue regions containing Eu-HP-DO3A-labeled cells remained significantly increased throughout the time course of examination in Bar graphs illustrate the measurement of MTR asym , which allows differentiation of (a) cell survival from (b) cell rejection. In C3H mice (a), MTR asym values in the region that contains Eu-HP-DO3A-labeled cells (cell graft) were significantly higher compared with septal regions (septum) in the same hearts and compared with corresponding regions after implantation of saline-labeled control cells (saline graft) in genetically identical mice at all measured time points. By 20 days after implantation, the mean MTR asym values in cell grafts were significantly lower when compared with values 1 day after implantation. In C57BL/6J mice (b), MTR asym values were increased 1 day after implantation in areas of Eu-HP-DO3A-labeled cells when compared with septal regions and saline-labeled controls and remained significantly increased 10 days after implantation but were similar 20 days after implantation. By 10 days, MTR asym values in the region of implanted Eu-HP-DO3A-labeled cells were significantly reduced compared with both the initial values 1 day after implantation and the corresponding values in C3H mice at identical time points. Bars represent P values less than .05 at identical time points. * 5 P , .05 versus day 1 in the same region, † = P , .05 versus cell graft in C3H mice at the same time point.
EXPERIMENTAL STUDIES: Tracking of Cell Survival or Rejection in Mouse Models of Cell Therapy
Pumphrey et al of C2C12 cells in C3H mice by 20 days after implantation. Importantly, labeling of C2C12 cells with Eu-HP-DO3A generated robust CEST contrast at the time of implantation that was preserved throughout the course of our study and did not affect the growth rate of C2C12 grafts. By 20 days after implantation, the moderate reduction in MTR asym values in Eu-HP-DO3A-labeled grafts likely resulted from dilution of label with cell division, which presents a boundary condition for the detection of surviving cells. In our study, we did not observe an eventual loss of CEST contrast; however, we were unable to perform continued examination beyond 20 days after implantation owing to an increase in arrhythmias and death caused by the growth of C2C12 grafts. MR imaging tracking of cells after cardiac transplantation was previously widely explored via iron oxide nanoparticle labeling; however, tissue retention of nanoparticles for up to 6 weeks after the death of labeled cells results in inaccurate detection of cell survival (2, (8) (9) (10) (11) (12) (13) . In this study, the rejection of Eu-HP-DO3A-labeled C2C12 cells in C57BL/6J mice resulted in rapid loss of CEST contrast. The clearance of Eu-HP-DO3A from myocardium after intravenous injection was previously demonstrated by using dynamic measurement of cardiac MTR asym for 30 minutes after injection (21) . In Eu-HP-DO3A-labeled cells undergoing rejection, Eu-HP-DO3A that is released after cell rupture is likely cleared through mechanisms similar to those observed previously. However, in this study, we did not examine whether removal of Eu-HP-DO3A by means of inflammatory mechanisms contributes to MTR asym normalization after rejection. Importantly, given renewed concerns about the accumulation of gadolinium in regions of the brain, even in individuals with preserved renal function (27, 28) , further studies are necessary to understand clearance of paramagnetic CEST agents after cell death.
The implantation of C2C12 cells in C3H and C57BL/6J mice models the two extreme outcomes of cell therapy: high survival with rapid proliferation that implantation and complete loss of CEST contrast within 20 days. Finally, assessment of graft size by applying a threshold MTR asym value was similar to that measured at histologic examination.
Myocardial implantation of C2C12 cells is an established cardiac cell therapy model for evaluating MR imaging cell-tracking techniques (13, 25, 26) . In a prior study, transgenic ferritin heavychain overexpressing C2C12 cells implanted into the hearts of C3H mice were visualized by using T2*-weighted MR imaging 3 weeks after implantation (25) . We observed similar engraftment imaging for serial tracking of cell survival or rejection after cardiac transplantation. In both models, grafts of viable Eu-HP-DO3A-labeled cells were clearly distinguishable from surrounding myocardium immediately after implantation. The implantation of salinelabeled cells as controls resulted in no changes in MTR asym values, regardless of cell fate and time. While tissues that contained surviving Eu-HP-DO3A-labeled cells demonstrated preserved CEST contrast for 20 days, the rejection of identical cells led to immediate reductions in MTR asym by 10 days after development of continuous wave approaches by using multichannel parallel transmit and receive technology will enable substantial reductions in required saturation energy. Finally, confining CEST imaging and histologic analysis to a limited number of sections limited the ability to obtain volumetric information about graft size. A more thorough validation of graft size measurement should be performed in a future study by comparing whole-heart cardiac CEST imaging to whole-heart histologic findings.
In conclusion, cardiac CEST cell tracking can serve as a tool for preclinical research of emerging methods to enhance the survival of implanted stem cells. Since CEST contrast is selectively activated, the combined use of CESTactive biomaterials (33) , CEST MR imaging reporter genes (16, 18, 32) , and multiagent paramagnetic CEST labeling of different cell populations (15) has the potential to demonstrate multiple processes that drive cell fate decisions in regenerative therapy. borders on teratoma formation (C3H) and complete rejection of implanted cells (C57BL/6J). With existing cell therapy approaches, near-complete rejection of implanted cells is typically observed, similar to that observed in our C57BL/6J model, with an ultimate goal of increasing cell survival in the direction observed in our C3H model. A number of combined therapeutic approaches are under investigation, including incorporation of biomaterials (29) , combined cell and gene therapy (30) , and pharmacologic stimulation to enhance recruitment of native mesenchymal cells (31) . The ability to noninvasively monitor the success of secondary interventions in promoting increased cell survival will be crucial in pushing forward the next generation of cell therapy approaches. While we accurately quantified the rejection of Eu-HP-DO3A-labeled cells in C57BL/6J mice, the sensitivity limits of cardiac CEST need to be investigated further.
The use of lanthanide (Ln)-based para magnetic CEST agents (Ln-HP-DO3A) represents a potential translational limitation, given renewed concern surrounding similarly formulated gadolinium-based contrast agents. While the concentration of chelated lanthanide metals is as high as 3-5 mmol/L in cells after hypotonic swelling (22) , even the immediate release of all intracellular Ln-HP-DO3A into the blood pool would result in concentrations that are orders of magnitude lower than those that occur after intravenous injection of similar contrast agents as part of routine MR imaging examination (Appendix E1 [online]). Further study is warranted as to whether labeling of cells with paramagnetic CEST agents induces changes in gene expression similar to those observed with iron oxide-based agents. However, emerging CEST MR imaging labels, including CEST-active reporter genes (16, 18, 32) and engineered nonmetallic CEST macromolecules (33, 34) , could be used in place of lanthanide metal-based labels. A secondary limitation to our study is the use of high radiofrequency saturation power to generate CEST contrast that would not be possible in clinical settings. While this may present an immediate obstacle, further
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